Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials
- 21 May 2010
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 9 (3), 217-229
- https://doi.org/10.1002/pst.439
Abstract
In recent years, we have seen an increasing trend of foreign data as part of clinical trial data submitted in new drug applications (NDA) to US Food and Drug Administration (FDA). To understand the design and analysis characteristics, we studied schizophrenia multi-regional clinical trials (MRCTs). The schizophrenia data set consisted of a total of 12 585 patients collected from 33 clinical trials with 63.8% patients from North America, the largest region. The data set constituted 10 schizophrenia drug programs in support of NDAs submitted to FDA from December 1993 to December 2005. Two main objectives were pursued. First, we investigated some study design issues including potential heterogeneity of treatment effect via meta analysis and placebo response pattern over time. Second, we performed empirical modeling in two ways, supervised and unsupervised, to explain potential impact of baseline covariates on treatment effect in MRCTs. Based on our analysis results, placebo response appeared to increase over time and primarily attributed to US region. On average, the observed treatment effect in the US was generally smaller than non-US region. Both supervised and unsupervised empirical modeling selected baseline Positive and Negative Syndrome Scale total score as one of the most important covariates explaining a treatment effect. Region also played a role in explaining potential treatment effect heterogeneity. When baseline body weight was considered as a covariate in an empiric model, our results indicated that it alone did not seem to be an important factor in explaining regional difference. Published in 2010 by John Wiley & Sons, Ltd.Keywords
This publication has 17 references indexed in Scilit:
- A Bias Correction in Testing Treatment Efficacy Under Informative Dropout in Clinical TrialsJournal of Biopharmaceutical Statistics, 2009
- Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients*International Journal Of Clinical Practice, 2009
- How Biased Are Indirect Comparisons, Particularly When Comparisons Are Made Over Time in Controlled Trials?Drug Information Journal, 2008
- Trends in the globalization of clinical trialsNature Reviews Drug Discovery, 2008
- Weight Gain Induced by Psychotropic DrugsObesity Management, 2007
- The 100-year epidemiology of schizophreniaSchizophrenia Research, 1997
- The Influence of Age and Sex on the Onset and Early Course of SchizophreniaThe British Journal of Psychiatry, 1993
- Reliability and validity of the positive and negative syndrome scale for schizophrenicsPsychiatry Research, 1988
- The Positive and Negative Syndrome Scale (PANSS) for SchizophreniaSchizophrenia Bulletin, 1987
- The Brief Psychiatric Rating ScalePsychological Reports, 1962